Poorly Soluble Drugs

The majority of NCEs in clinical development, and pharmaceutical products on the market, contain poorly soluble drugs.  Thus there is significant demand for new and improved formulation approaches to develop these drugs.  Nano-technology is driving the solution for many of these difficult formulation challenges, providing new options for pharmaceutical products to be developed with improved biopharmaceutical properties.  Using these technologies, products with lower doses, reduced food effects, less painful injections, more rapid onset-of-action, improved palatability and many other outcomes are made possible.

Formulating poorly water soluble drugs has traditionally been approached by creating new salt forms or co-crystals, micronizing the drug substance, or creating lipidic emulsions.  As drugs become even more insoluble, more sophisticated approaches are required.  Ascendia® provides the parallel investigation of multiple technical solutions to see which one works best for a particular molecule.  All of these approaches have one common goal – to improve the bioavailability of the drug by increasing the rate and extent of its dissolution in biological fluid.